GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Summit Therapeutics PLC (LSE:SUMM) » Definitions » Equity-to-Asset

Summit Therapeutics (LSE:SUMM) Equity-to-Asset : 0.25 (As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Summit Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Summit Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was £34.79 Mil. Summit Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was £139.13 Mil.

The historical rank and industry rank for Summit Therapeutics's Equity-to-Asset or its related term are showing as below:

LSE:SUMM' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.09   Med: 0.65   Max: 0.78
Current: 0.38

During the past 13 years, the highest Equity to Asset Ratio of Summit Therapeutics was 0.78. The lowest was -0.09. And the median was 0.65.

LSE:SUMM's Equity-to-Asset is ranked worse than
71.78% of 1566 companies
in the Biotechnology industry
Industry Median: 0.66 vs LSE:SUMM: 0.38

Summit Therapeutics Equity-to-Asset Historical Data

The historical data trend for Summit Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Summit Therapeutics Equity-to-Asset Chart

Summit Therapeutics Annual Data
Trend Jan14 Jan15 Jan16 Jan17 Jan18 Jan19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.70 0.78 0.74 0.19 0.38

Summit Therapeutics Quarterly Data
Apr19 Jul19 Oct19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.52 0.50 0.46 0.38 0.25

Competitive Comparison of Summit Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, Summit Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Summit Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Summit Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Summit Therapeutics's Equity-to-Asset falls into.



Summit Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Summit Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=61.377/160.33
=

Summit Therapeutics's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=34.793/139.127
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Summit Therapeutics  (LSE:SUMM) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Summit Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Summit Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Summit Therapeutics (LSE:SUMM) Business Description

Traded in Other Exchanges
Address
2882 Sand Hill Road, Suite 106, Menlo Park, CA, USA, 94025
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its lead CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Summit Therapeutics (LSE:SUMM) Headlines

No Headlines